The major goal of this project is to develop clinical protocols to test the effectiveness of recombinant growth factors at enhancing the rapidity and durability of hematopoietic regeneration inpatients undergoing autologous marrow transplantation (AMT). A secondary goal is to examine the reliability of culture assays for predicting clinical efficacy. A series of clinical trials is planned to test the effect of recombinant human growth factors in patients undergoing AMT. A Phase I-II dose searching study using recombinant GM-CSF in patients undergoing AMT for lymphoidneoplasia has been completed and a non-toxic, possibly efficacious regimen has been determined (250 mu g/kg/day by 2 hr infusion for 21 days). This regimen will be employed in a soon to begin Phase III trial examining the efficacy of rhGM-CSF on improving the rapidity and durability of engraftment in patients undergoing AMT for lymphoid malignancy. The trial design is randomized and double-blinded and has a planned accrual of 40 patients. An additional trial which has begun examines the effectiveness of GM-CSF in patients with late graft failure following AMT. Subsequent Phase I-II studies will use IL-3 and IL-l, alone and in combination with GM-CSF. In conjunction with these in vivo studies, a limited series of in vitro studies will examine the predictive effect of determination of the number of committed progenitor infused and their in vitro responsiveness to GM-CSF on clinical efficacy. The effect of growth factors on recovery of blood and marrow in vitro colony- forming cells from patients under clinical study will also be determined.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Bensinger, W I (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23:442-8
Bensinger, William (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 26:480-92
Bensinger, William I (2007) Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract Res Clin Haematol 20:783-95
Bensinger, William I (2007) Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci 12:4384-92
Zaucha, Renata E; Buckner, Dean C; Barnett, Todd et al. (2006) Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 64:227-34
Bensinger, W I (2006) The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 20:1683-9
Bensinger, William I (2004) The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. J Natl Compr Canc Netw 2:371-8
Bensinger, William I (2004) The current status of hematopoietic stem cell transplantation for multiple myeloma. Clin Adv Hematol Oncol 2:46-52
Yusuf, U; Frangoul, H A; Gooley, T A et al. (2004) Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 33:805-14
Einsele, H; Bamberg, M; Budach, W et al. (2003) A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant 32:593-9

Showing the most recent 10 out of 150 publications